Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade B 172.48 1.66% 2.82
SHPG closed up 1.66 percent on Wednesday, December 12, 2018, on 1.39 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical SHPG trend table...

Date Alert Name Type % Chg
Dec 12 Calm After Storm Range Contraction 0.00%
Dec 12 Narrow Range Bar Range Contraction 0.00%
Dec 12 Gapped Up Strength 0.00%
Dec 11 Calm After Storm Range Contraction 1.66%
Dec 11 Stochastic Reached Oversold Weakness 1.66%
Dec 11 Multiple of Ten Bearish Other 1.66%
Dec 11 Strong but Oversold Other 1.66%
Dec 11 Inside Day Range Contraction 1.66%
Dec 11 Down 3 Days in a Row Weakness 1.66%
Dec 11 Oversold Stochastic Weakness 1.66%

Older signals for SHPG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 182.47
52 Week Low 122.9082
Average Volume 1,423,267
200-Day Moving Average 165.4733
50-Day Moving Average 175.578
20-Day Moving Average 175.1025
10-Day Moving Average 173.063
Average True Range 3.5335
ADX 16.16
+DI 22.2301
-DI 32.4501
Chandelier Exit (Long, 3 ATRs ) 171.8695
Chandelier Exit (Short, 3 ATRs ) 179.2605
Upper Bollinger Band 181.5109
Lower Bollinger Band 168.6941
Percent B (%b) 0.3
BandWidth 7.319599
MACD Line -1.3777
MACD Signal Line -0.8739
MACD Histogram -0.5038
Fundamentals Value
Market Cap 51.38 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 77.35
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.53%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 174.76
Resistance 3 (R3) 174.72 173.92 174.38
Resistance 2 (R2) 173.92 173.34 173.94 174.25
Resistance 1 (R1) 173.20 172.98 173.56 173.24 174.13
Pivot Point 172.40 172.40 172.58 172.42 172.40
Support 1 (S1) 171.68 171.82 172.04 171.72 170.83
Support 2 (S2) 170.88 171.46 170.90 170.71
Support 3 (S3) 170.16 170.88 170.58
Support 4 (S4) 170.20